The invention relates to a method for producing a composition, in particular a gel composition, more in particular a glucose gel, the method comprising the steps of providing an aqueous glucose solution, adding at least one first fraction of acid, adding a fraction of a gelling agent and mixing of the solution and gelling agent such that a composition is obtained. A container is subsequently filled with said composition.

The invention relates to a method for producing a composition, in particular a gel composition, more in particular a glucose gel, the method comprising the steps of providing an aqueous glucose solution, adding at least one first fraction of acid, adding a fraction of a gelling agent and mixing of the solution and gelling agent such that a composition is obtained. A container is subsequently filled with said composition.

The invention relates to a medical product for preventing or correcting vitamin A deficiency in a patient comprising a lipid emulsion in a flexible container, the lipid emulsion comprising (a) vitamin A in the lipid phase of the lipid emulsion, (b) optionally additionally vitamin D, vitamin E and/or vitamin K in the lipid phase of the lipid emulsion, and (c) no more than 1.5 ppm dissolved oxygen (DO), (d) wherein the pH of the lipid emulsion is from 5 to 9.

The invention relates to a medical product for preventing or correcting vitamin A deficiency in a patient comprising a lipid emulsion in a flexible container, the lipid emulsion comprising (a) vitamin A in the lipid phase of the lipid emulsion, (b) optionally additionally vitamin D, vitamin E and/or vitamin K in the lipid phase of the lipid emulsion, and (c) no more than 1.5 ppm dissolved oxygen (DO), (d) wherein the pH of the lipid emulsion is from 5 to 9.

The invention discloses an application of bacteria in preparation of a synergist for an immune checkpoint inhibitor. The bacteria are active bacteria or inactive whole-cell gut microbiota. By using a monobacterial oral preparation of human endogenous gut microbiota Alistipes combined with an immune checkpoint inhibitor, an anti-tumor immune protective response and an effect of remodeling gut microbiota is generated by stimulation of oral administration of active human commensal gut microbiota or inactive whole-cell human commensal gut microbiota, which significantly enhances an efficacy of the immune checkpoint inhibitor on multiple tumor species, enhances anti-tumor immune function, is conducive to improving the response rate of cancer immunotherapy populations, and has better safety, prolongs overall survival time of cancer patients, expands cancer patient population benefited from cancer immunotherapy (immunotherapy checkpoint inhibitors), provides new combination therapy regimens and therapeutic drugs to treat immune checkpoint inhibitor-refractory tumor patients, and expands the patient benefited from cancer immunotherapy.

The invention discloses an application of bacteria in preparation of a synergist for an immune checkpoint inhibitor. The bacteria are active bacteria or inactive whole-cell gut microbiota. By using a monobacterial oral preparation of human endogenous gut microbiota Alistipes combined with an immune checkpoint inhibitor, an anti-tumor immune protective response and an effect of remodeling gut microbiota is generated by stimulation of oral administration of active human commensal gut microbiota or inactive whole-cell human commensal gut microbiota, which significantly enhances an efficacy of the immune checkpoint inhibitor on multiple tumor species, enhances anti-tumor immune function, is conducive to improving the response rate of cancer immunotherapy populations, and has better safety, prolongs overall survival time of cancer patients, expands cancer patient population benefited from cancer immunotherapy (immunotherapy checkpoint inhibitors), provides new combination therapy regimens and therapeutic drugs to treat immune checkpoint inhibitor-refractory tumor patients, and expands the patient benefited from cancer immunotherapy.

An apparatus for vaccine generation includes a syringe with a cavity that includes a solution with photosensitizers. Microbial particles are added to the solution. A light source is capable of emitting one or more wavebands of light that are effectively absorbed by the one photosensitizers to generate singlet oxygen in the solution and other radical species that rapidly react with and damage lipids, proteins, DNA, and RNA of the microbial particles. This damage produces immunogens that can be applied as a vaccine to viruses and other infectious microbial particles. A plunger that fits within a proximal opening in the syringe is used for forcing the solution including the immunogens through the filter and out of the syringe while the photosensitizers, debris and unwanted microbial particles are trapped within the filter.

The present invention pertains to an enzyme preparation obtained from e-beam irradiated animal tissue, such as porcine pancreas. The present invention also pertains to methods for making such enzyme preparations, pharmaceutical compositions comprising such enzymes preparations, and methods for using such pharmaceutical compositions and enzyme preparations.

The present invention pertains to an enzyme preparation obtained from e-beam irradiated animal tissue, such as porcine pancreas. The present invention also pertains to methods for making such enzyme preparations, pharmaceutical compositions comprising such enzymes preparations, and methods for using such pharmaceutical compositions and enzyme preparations.

The present invention pertains to an enzyme preparation obtained from e-beam irradiated animal tissue, such as porcine pancreas. The present invention also pertains to methods for making such enzyme preparations, pharmaceutical compositions comprising such enzymes preparations, and methods for using such pharmaceutical compositions and enzyme preparations.